413 related articles for article (PubMed ID: 25698488)
1. No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus.
Helfer-Hungerbuehler AK; Spiri AM; Riond B; Grest P; Boretti FS; Hofmann-Lehmann R
Vaccine; 2015 Mar; 33(13):1578-85. PubMed ID: 25698488
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.
Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M
Clin Vaccine Immunol; 2015 Jul; 22(7):798-805. PubMed ID: 25972402
[TBL] [Abstract][Full Text] [Related]
3. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine.
Harbour DA; Gunn-Moore DA; Gruffydd-Jones TJ; Caney SM; Bradshaw J; Jarrett O; Wiseman A
Vaccine; 2002 Jul; 20(23-24):2866-72. PubMed ID: 12126896
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow up of feline leukemia virus infection and characterization of viral RNA loads using molecular methods in tissues of cats with different infection outcomes.
Helfer-Hungerbuehler AK; Widmer S; Kessler Y; Riond B; Boretti FS; Grest P; Lutz H; Hofmann-Lehmann R
Virus Res; 2015 Feb; 197():137-50. PubMed ID: 25553598
[TBL] [Abstract][Full Text] [Related]
5. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
Grosenbaugh DA; Leard T; Pardo MC
J Am Vet Med Assoc; 2006 Mar; 228(5):726-7. PubMed ID: 16506935
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge.
Stuke K; King V; Southwick K; Stoeva MI; Thomas A; Winkler MT
Vaccine; 2014 May; 32(22):2599-603. PubMed ID: 24662705
[TBL] [Abstract][Full Text] [Related]
8. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge.
Langhammer S; Hübner J; Jarrett O; Kurth R; Denner J
Antiviral Res; 2011 Jan; 89(1):119-23. PubMed ID: 21108970
[TBL] [Abstract][Full Text] [Related]
9. Real-time PCR investigation of feline leukemia virus proviral and viral RNA loads in leukocyte subsets.
Cattori V; Pepin AC; Tandon R; Riond B; Meli ML; Willi B; Lutz H; Hofmann-Lehmann R
Vet Immunol Immunopathol; 2008 May; 123(1-2):124-8. PubMed ID: 18304650
[TBL] [Abstract][Full Text] [Related]
10. Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats.
Pepin AC; Tandon R; Cattori V; Niederer E; Riond B; Willi B; Lutz H; Hofmann-Lehmann R
Virus Res; 2007 Jul; 127(1):9-16. PubMed ID: 17434224
[TBL] [Abstract][Full Text] [Related]
11. Survey of the feline leukemia virus infection status of cats in Southern Germany.
Englert T; Lutz H; Sauter-Louis C; Hartmann K
J Feline Med Surg; 2012 Jun; 14(6):392-8. PubMed ID: 22403413
[TBL] [Abstract][Full Text] [Related]
12. Feline leukemia virus immunity induced by whole inactivated virus vaccination.
Torres AN; O'Halloran KP; Larson LJ; Schultz RD; Hoover EA
Vet Immunol Immunopathol; 2010 Mar; 134(1-2):122-31. PubMed ID: 20004483
[TBL] [Abstract][Full Text] [Related]
13. Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats.
Hofmann-Lehmann R; Huder JB; Gruber S; Boretti F; Sigrist B; Lutz H
J Gen Virol; 2001 Jul; 82(Pt 7):1589-1596. PubMed ID: 11413369
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection.
Clark N; Kushner NN; Barrett CB; Kensil CR; Salsbury D; Cotter S
J Am Vet Med Assoc; 1991 Nov; 199(10):1433-43. PubMed ID: 1666099
[TBL] [Abstract][Full Text] [Related]
15. Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up.
Hofmann-Lehmann R; Cattori V; Tandon R; Boretti FS; Meli ML; Riond B; Pepin AC; Willi B; Ossent P; Lutz H
Vaccine; 2007 Jul; 25(30):5531-9. PubMed ID: 17240486
[TBL] [Abstract][Full Text] [Related]
16. Association between endogenous feline leukemia virus loads and exogenous feline leukemia virus infection in domestic cats.
Tandon R; Cattori V; Pepin AC; Riond B; Meli ML; McDonald M; Doherr MG; Lutz H; Hofmann-Lehmann R
Virus Res; 2008 Jul; 135(1):136-43. PubMed ID: 18407367
[TBL] [Abstract][Full Text] [Related]
17. Recombinant feline leukemia virus (FeLV) variants establish a limited infection with altered cell tropism in specific-pathogen-free cats in the absence of FeLV subgroup A helper virus.
Bechtel MK; Hayes KA; Mathes LE; Pandey R; Stromberg PC; Roy-Burman P
Vet Pathol; 1999 Mar; 36(2):91-9. PubMed ID: 10098636
[TBL] [Abstract][Full Text] [Related]
18. Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection.
Major A; Cattori V; Boenzli E; Riond B; Ossent P; Meli ML; Hofmann-Lehmann R; Lutz H
Vet Res; 2010; 41(2):17. PubMed ID: 19861115
[TBL] [Abstract][Full Text] [Related]
19. The location in cartilage of infectious retrovirus in cats infected with feline leukemia virus.
Arnoczky SP; Swenson C; Egerbacher M; Gardner K; Caballero O; Burns M
J Bone Joint Surg Am; 2007 Sep; 89(9):2030-6. PubMed ID: 17768202
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three feline leukaemia virus (FeLV) point-of-care antigen test kits using blood and saliva.
Westman ME; Malik R; Hall E; Sheehy PA; Norris JM
Comp Immunol Microbiol Infect Dis; 2017 Feb; 50():88-96. PubMed ID: 28131385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
